MeiraGTx/$MGTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MeiraGTx
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
- Ticker
- $MGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 386
- Headquarters
- New York, United States
- Website
- www.meiragtx.com
MeiraGTx Metrics
BasicAdvanced
$780M
9.19
$0.87
1.07
-
Price and volume
Market cap
$780M
Beta
1.07
52-week high
$15.35
52-week low
$6.62
Average daily volume
711K
Financial strength
Current ratio
4.625
Quick ratio
4.088
Long term debt to equity
0.61
Total debt to equity
0.622
Interest coverage (TTM)
23.17%
Profitability
EBITDA (TTM)
191.997
Gross margin (TTM)
97.20%
Net profit margin (TTM)
19.48%
Operating margin (TTM)
44.84%
Effective tax rate (TTM)
3.67%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
37.47%
Return on equity (TTM)
89.50%
Valuation
Price to earnings (TTM)
9.191
Price to revenue (TTM)
1.742
Price to book
3.62
Price to tangible book (TTM)
3.62
Price to free cash flow (TTM)
-25.34
Free cash flow yield (TTM)
-3.95%
Free cash flow per share (TTM)
-0.315
Growth
Revenue change (TTM)
1,365.90%
Earnings per share change (TTM)
-141.14%
3-year revenue growth (CAGR)
291.67%
3-year earnings per share growth (CAGR)
-29.71%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Analyst projections of the future price of MeiraGTx stock.
Bulls say / Bears say
AAV2-hAQP1 showed symptom and saliva-flow improvements lasting three years in a 24-person Phase 1 study, and the FDA granted it Breakthrough Therapy designation. A positive pivotal read-out could support a filing. (MeiraGTx)
MeiraGTx reacquired bota-vec for $25 million and plans global regulatory filings in 2026; its manufacturing and quality-control facilities are commercially licensed. XLRP has no approved treatment, offering potential for a first-to-market therapy if regulators accept the evidence. (MeiraGTx)
The company secured up to $400 million from Oberland Capital, including an initial $125 million in royalty financing, and says its available resources should fund operations into the second half of 2028. That eases near-term funding pressure as it approaches key trial and filing milestones. (MeiraGTx)
Bota-vec failed to improve vision-guided mobility, the primary endpoint in its Phase 3 trial. MeiraGTx is pursuing filings despite that setback, leaving its approval prospects uncertain. (Fierce Biotech)
MeiraGTx reported $160.7 million of second-quarter net income, but also recognised $204.6 million of related-party licence revenue from granting Reogen rights to AAV-GAD and AAV-BDNF. That transaction-driven profit does not yet demonstrate a recurring earnings base from product sales. (MeiraGTx)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MeiraGTx
Fund name | Fund size | $MGTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.